Evidence map›Paper›PMID 37444553›Full record

ArticleCancers2023

Prophylactic A-Blockers for Radiotherapy-Induced Lower Urinary Tract Symptoms in Men with Prostate Cancer: A Phase III Randomized Trial.

Tamim Niazi, Edmond Kaldany, Steven Tisseverasinghe, Talía Malagón, Boris Bahoric, Victor McPherson, Alexis Rompre-Brodeur, Maurice Anidjar

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 82% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tamim NiaziDivision of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Edmond KaldanyDivision of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Steven TisseverasingheDivision of Radiation Oncology, Department of Oncology, McGill University, Gatineau, QC J8V 3R2, Canada.
Talía MalagónDivision of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Boris BahoricDivision of Radiation Oncology, Department of Oncology, McGill University, Montreal, QC H3A 0G4, Canada.
Victor McPhersonDivision of Urology, Department of Surgery, McGill University, Montreal, QC H3A 0G4, Canada.
Alexis Rompre-BrodeurDivision of Urology, Department of Surgery, McGill University, Montreal, QC H3A 0G4, Canada.ORCID 0000-0001-8177-0514
Maurice AnidjarDivision of Urology, Department of Surgery, McGill University, Montreal, QC H3A 0G4, Canada.
McGill University · CA

Funding

Allergan (Canada) TBD
6 · The paper itself

Abstract

purposeThe present phase III randomized trial assessed the efficacy of prophylactic versus therapeutic α-blockers at improving RI-LUTSs in prostate cancer patients receiving external beam radiotherapy (EBRT).

methodsA total of 148 prostate cancer patients were randomized 1:1 to receive either prophylactic silodosin on day one of EBRT or the occurrence of RI-LUTSs. LUTSs were quantified using the international prostate symptom score (IPSS) at regular intervals during the study. The primary endpoint was the change in the IPSS from baseline to the last day of radiotherapy (RT). Secondary endpoints included changes in IPSS from baseline to 4 weeks and 12 weeks after the start of RT.

resultsPatient demographics, baseline IPSS, and prescribed radiation doses were balanced between arms. On the last day of RT, the mean IPSS was 14.8 (SD 7.6) in the experimental arm and 15.7 (SD 8.5) in the control arm (

conclusionProphylactic α-blockers were not effective at significantly reducing RI-LUTSs in prostate cancer patients treated with EBRT. Treating patients with α-blockers at the onset of RI-LUTSs will avoid unnecessary drug exposure and toxicity.

Indexed as

lower urinary tract symptomsprophylactic alpha-blockersprostate cancerradiation therapy

Identifiers

PMID37444553
PMCPMC10341310
OpenAlexW4382982544

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.